Sarah P. Moyle
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Journal: The Lancet. Microbe
Published: October 05, 2023
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.
Journal: Biotechnology and bioengineering
Published: February 15, 2022
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
Journal: Frontiers in immunology
Published: April 13, 2021
Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
Journal: Regenerative medicine
Published: November 30, 2018
Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells.
Journal: NPJ vaccines
Published: March 20, 2018
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Journal: The Journal of infectious diseases
Published: October 23, 2014
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 10, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 26, 2014
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 23, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.
Journal: Nature communications
Published: March 05, 2013
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 24, 2012
Last Updated: 09/26/2026